India became “Aatmanirbhar” in 38 APIs: HM

With 95% dependency on one country, the vulnerability was evident.

242
Medicine
Picture: Pixabay

Last Updated on August 10, 2023 by The Health Master

India: Self-Reliance in API manufacturing

In a significant revelation, Union Health Minister Mansukh Mandaviya unveiled India’s transformative journey towards self-reliance in active pharmaceutical ingredients (APIs) at the Healthcare Summit hosted by the prestigious Indian Institute of Management Ahmedabad (IIMA).

Referring to the crucial juncture of the Doklam standoff in 2017, Mandaviya outlined the nation’s resolute commitment to becoming ‘aatmanirbhar‘ (self-reliant) in API production, reflecting the determined shift away from dependency on a single source.

Mandaviya commended this pivotal step towards enhancing India’s pharmaceutical capabilities, heralding a new era of self-sufficiency.

A Strategic Transformation:

During his address, Mandaviya shared insights into India’s strategic transformation:

Reducing Dependency:

The minister underscored that during the Doklam crisis, India realized the critical need to reduce its overreliance on a single source for APIs.

With 95% dependency on one country, the vulnerability was evident.

The realization prompted a strategic shift, setting the stage for comprehensive planning towards self-reliance.

Progress in API Production:

Mandaviya proudly stated that significant strides had been made in the production of APIs. Out of 54 types of APIs, 38 have been successfully manufactured within the past 18 months.

This impressive accomplishment was largely attributed to the implementation of production-linked incentives (PLIs), further bolstering India’s pharmaceutical independence.

Stressing Research and Development:

Emphasizing the role of research and development (R&D), the minister pointed out the disparity between international and Indian pharmaceutical companies in plowing back profits for R&D.

While global giants allocate 10–25% of profits to R&D, Indian companies currently allocate only 6–7%.

Pharma Research Policy:

The implementation of the Pharma Research Policy, overseen by the Indian Council of Medical Research (ICMR), was highlighted.

Under this policy, 125 researchers will be granted up to Rs 1 crore each for developing groundbreaking ideas.

Moreover, companies will receive incentives of up to Rs 125 crore, boosting innovation and fostering growth in the sector.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news